14-day Premium Trial Subscription Try For FreeTry Free
$4.57
+0.160 (+3.63%)
At Close: May 01, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $4.25 $5.48 Wednesday, 1st May 2024 QURE stock ended at $4.57. This is 3.63% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 6.31% from a day low at $4.36 to a day high of $4.64.
90 days $4.25 $6.85
52 weeks $4.25 $22.48

Historical uniQure N.V. prices

Date Open High Low Close Volume
Jan 14, 2022 $19.22 $20.22 $19.12 $20.21 533 000
Jan 13, 2022 $19.83 $20.15 $19.32 $19.39 356 400
Jan 12, 2022 $19.44 $20.16 $19.30 $19.76 479 200
Jan 11, 2022 $19.37 $20.01 $19.27 $19.37 270 400
Jan 10, 2022 $19.39 $19.54 $18.70 $19.50 731 100
Jan 07, 2022 $19.65 $20.51 $19.45 $19.50 361 400
Jan 06, 2022 $19.61 $19.91 $19.01 $19.60 436 800
Jan 05, 2022 $20.72 $20.99 $19.52 $19.52 617 468
Jan 04, 2022 $21.40 $21.61 $20.40 $20.71 469 599
Jan 03, 2022 $20.96 $21.85 $20.68 $21.50 712 101
Dec 31, 2021 $20.99 $21.67 $20.60 $20.74 652 233
Dec 30, 2021 $20.54 $21.60 $20.36 $20.87 1 059 157
Dec 29, 2021 $20.72 $20.95 $20.41 $20.62 682 992
Dec 28, 2021 $21.54 $22.57 $20.80 $20.84 474 968
Dec 27, 2021 $22.24 $22.50 $21.17 $21.48 682 205
Dec 23, 2021 $21.90 $22.43 $21.49 $22.25 552 335
Dec 22, 2021 $21.49 $22.25 $21.22 $21.74 513 482
Dec 21, 2021 $22.10 $22.27 $21.08 $21.67 905 382
Dec 20, 2021 $21.22 $22.10 $20.91 $21.86 1 625 781
Dec 17, 2021 $19.88 $21.48 $19.66 $21.23 3 875 002
Dec 16, 2021 $25.50 $25.64 $19.50 $20.24 6 239 648
Dec 15, 2021 $27.90 $28.90 $26.76 $28.75 532 662
Dec 14, 2021 $28.34 $28.84 $27.58 $28.12 252 873
Dec 13, 2021 $28.47 $29.61 $27.93 $28.71 313 607
Dec 10, 2021 $28.11 $28.59 $27.52 $28.25 268 627
Click to get the best stock tips daily for free!

About uniQure N.V.

uniQure N.V. uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas... QURE Profile

Golden Star

Ticker Date Change Price
HRB Apr 29 1.00% $47.23
LYG Apr 29 0.391% $2.56
ORA Apr 29 1.95% $64.48
ETSY Apr 26 3.43% $67.43
DHT Apr 24 0.98% $11.28
LPLA Apr 19 1.10% $262.59
MLI Apr 19 7.29% $52.28
PFLT Apr 18 1.33% $11.25
DOOR Apr 18 0.94% $131.39
OCSL Apr 17 0.360% $19.43
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT